<DOC>
	<DOCNO>NCT00853307</DOCNO>
	<brief_summary>This open-label , multicenter , single-arm , phase 2 study MLN8237 treatment patient platinum-refractory platinum-resistant epithelial ovarian , fallopian tube , primary peritoneal carcinoma .</brief_summary>
	<brief_title>MLN8237 Treatment Patients With Ovarian , Fallopian Tube , Peritoneal Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>1 . Female patient 18 year old 2 . Histologically cytologically confirm epithelial ovarian , fallopian tube , primary peritoneal carcinoma . 3 . Eastern Cooperative Oncology Group performance status 0 1 4 . Postmenopausal least 1 year , OR Surgically sterile , OR If childbearing potential , agree 2 effective method nonhormonal contraception , agree completely abstain heterosexual intercourse 5 . Able provide write informed consent . 6 . Within 7 day study : Absolute neutrophil ( ANC ) ≥ 1,500/μL Platelets ≥100,000/ μL Total bilirubin must &lt; 1.5 time upper limit normal ( ULN ) Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) must ≤ 2.5 time ULN . AST ALT may elevate 5 time ULN ascribe metastatic liver disease . Creatinine clearance ≥ 30 mL/minute 7 . Platinumrefractory resistant disease 8 . Measurable disease Response Evaluation Criteria Solid Tumors ( RECIST ) OR CA 125 level &gt; 40 units/mL AND clinical evidence disease 9 . Recovered effect prior therapy 1 . Pregnant lactate 2 . Serious illness could interfere protocol completion 3 . Investigational treatment 28 day prior first dose . 4 . Maximum 4 prior systemic therapy : 2 platinumbased , 1 nonplatinum cytotoxic , 1 biological 5 . Known Central Nervous System metastases 6 . Prior allogeneic bone marrow organ transplantation 7 . Radiotherapy within 21 day prior first dose 8 . Radiotherapy &gt; 25 % bone marrow 9 . Major surgery , infection require systemic antibiotic therapy within 14 day prior first dose 10 . Inability swallow orally administer medication 11 . Diagnosis treatment another malignancy within 2 year precede first dose study drug except nonmelanoma skin cancer situ malignancy completely resect 12 . Known history human immunodeficiency virus ( HIV ) infection , hepatitis B , hepatitis C .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>